Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (4580)	8/4/2010 10:02:08 AM
From: bob zagorin	Respond to of 4676

Vical to Present at Canaccord Genuity Growth Conference Press Release Source: Vical Incorporated On Wednesday August 4, 2010, 6:30 am EDT SAN DIEGO, Aug. 4, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL - News) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies and development programs at the Canaccord Genuity 30th Annual Growth Conference (Boston, August 10 -- 12). A webcast of Mr. Samant's presentation at the conference will be available live (4:30 p.m. EDT on Wednesday, August 11) and archived through the Events page in the Investors section of the Vical website at www.vical.com. About Vical Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.